Goldman Sachs Says Correction Could Be Coming: 5 Safe Dividend Stocks From the Conviction List24/7 Wall Street • 01/23/26
Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris TisiGlobeNewsWire • 01/22/26
Johnson & Johnson (JNJ) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 01/21/26
J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive SalesZacks Investment Research • 01/21/26
Johnson & Johnson reports Q4 earnings beat, issues 2026 guidance above forecastsProactive Investors • 01/21/26
J&J's Guidance Wallops Views, But Boston Scientific, Medtronic Take A TollInvestors Business Daily • 01/21/26
J&J expects to hit $100 billion in revenue next year after new strategy pays offMarket Watch • 01/21/26
Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga • 01/21/26
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare PlanZacks Investment Research • 01/19/26